Literature DB >> 21874283

What is the role of chemotherapy in endometrial cancer?

Thomas Hogberg1.   

Abstract

Adjuvant pelvic radiotherapy has the potential to eradicate micrometastases within the irradiated field but has not resulted in survival improvements in randomized studies. This illustrates the need for systemic therapy. Chemotherapy, mainly with anthracyclines, platinum compounds, and taxanes, renders high response rates although this unfortunately translates in only modest improvements in progression-free and overall survival. Better systemic treatments need to be developed. Investigations of the molecular mechanisms of endometrial cancer have identified possible targets for therapy. In advanced endometrial cancer one study shows that chemotherapy is better than whole abdominal radiotherapy, while in the adjuvant situation the combination of chemotherapy and radiotherapy appears promising.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21874283     DOI: 10.1007/s11912-011-0192-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  41 in total

1.  Quo vadis with targeted drugs in the 21st century?

Authors:  Jonas Bergh
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

2.  Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.

Authors:  Chad M Michener; Gertrude Peterson; Barbara Kulp; Kenneth D Webster; Maurie Markman
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

3.  Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma.

Authors:  Takahide Arimoto; Shunsuke Nakagawa; Toshiharu Yasugi; Hiroyuki Yoshikawa; Kei Kawana; Tetsu Yano; Yuji Taketani
Journal:  Gynecol Oncol       Date:  2006-09-22       Impact factor: 5.482

4.  Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Franco M Muggia; John A Blessing; Joel Sorosky; Gary C Reid
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

5.  Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.

Authors:  P J Hoskins; K D Swenerton; J A Pike; F Wong; P Lim; C Acquino-Parsons; N Lee
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

6.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

Authors:  J Tate Thigpen; Mark F Brady; Howard D Homesley; John Malfetano; Brent DuBeshter; Robert A Burger; Shu Liao
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

7.  Liposomal doxorubicin: a phase II trial.

Authors:  Giancarlo Balbi; Serena Visconti; Antonietta Monteverde; Maria-Amparo Manganaro; Antonio Cardone
Journal:  Acta Biomed       Date:  2007-12

8.  Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.

Authors:  B Sorbe; H Andersson; K Boman; P Rosenberg; M Kalling
Journal:  Int J Gynecol Cancer       Date:  2007-10-18       Impact factor: 3.437

Review 9.  Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

Authors:  C E Humber; J F Tierney; R P Symonds; M Collingwood; J Kirwan; C Williams; J A Green
Journal:  Ann Oncol       Date:  2006-12-05       Impact factor: 32.976

10.  A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.

Authors:  S Pignata; G Scambia; C Pisano; E Breda; M Di Maio; S Greggi; G Ferrandina; D Lorusso; V Zagonel; A Febbraro; N Riva; V De Rosa; C Gallo; F Perrone
Journal:  Br J Cancer       Date:  2007-05-08       Impact factor: 7.640

View more
  2 in total

Review 1.  'BRCAness' and its implications for platinum action in gynecologic cancer.

Authors:  Franco Muggia; Tamar Safra
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

2.  Novel dihydroartemisinin dimer containing nitrogen atoms inhibits growth of endometrial cancer cells and may correlate with increasing intracellular peroxynitrite.

Authors:  Yan Zhu; Christian Klausen; Jieyun Zhou; Xiangjie Guo; Yu Zhang; Hua Zhu; Zhao Li; Jung-Chien Cheng; Shuwu Xie; Wenjie Yang; Ying Li; Peter C K Leung
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.